Communique from the Annual General Meeting of STENOCARE A/S

Today, on May 16th, 2019, the Annual General Meeting of STENOCARE A/S (“STENOCARE” or the “Company”) was held. Below follows a summary of the established decisions. All decisions were taken with the required majority.

The Board of Directors’ report on the Company’s business in the past year

The general meeting took note of the Board of Directors’ report on the Company’s activities in 2018.

Presentation of the audited annual report for 2017/18 for approval

The general meeting unanimously adopted the audited annual report for 2017/18.

Decision regarding use of surplus or coverage of losses according to the approved annual report

The general meeting decided that use of surplus or coverage of losses shall be made in accordance with the approved annual report.

Election of members to the Board of Directors

The general meeting decided to elect Ian Abramowitz as new Board member and to re-elect Marianne Wier, Jeppe Bo Petersen, Søren Melsing Frederiksen and Rolf Steno to the Board of Directors until the next Annual General Meeting. Following the general meeting, the Board of Directors decided to re-elect Marianne Wier as Chairman of the Board.

Appointment of auditor

The general meeting decided that the Company’s current auditor, Beierholm, is re-elected until the next Annual General Meeting.

Changing the objects

The general meeting approved the Board’s decision to change the objects of STENOCARE A/S. The new objects will be: “The Company's purpose is to do business by scientific work, manufacturing, development, processing, import, sale and distribution of palliative products.”

Changing the authorization for share capital increase

The general meeting decided to give the Board of Directors an authorization for share capital increase until 31 May 2022. In this period the Board of Directors is authorized to make one or more capital increases whereby a total amount of up to DKK 50,000,000 can be added to the Company by issuing new shares.

Giving an authorization to the Board of Directors to issue Warrants with the corresponding capital increase

The general meeting authorized the Board of Directors to issue a warrant program with the corresponding capital increase. The warrant program includes an authorization to the Board of Directors to issue 400,000 shares of 0.08 in the period to 31 May 2022 to employees with competences to the benefit of the Company. Warrants cannot be issued to the Board of Directors, the CEO and the founders.

Other

The general meeting decided to authorize the Board, or the one the Board appoints, to make any minor adjustments in the Annual General Meeting’s resolutions that may prove necessary when registering a decision.

Allerød, May 16th, 2019

The Board of Directors of STENOCARE A/S

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

Phone: +45 31770060

E-mail: presse@stenocare.com

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot program. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers medical cannabis oil, that comply with the strict Danish regulatory requirements. STENOCARE is also developing a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.

About Us

STENOCARE A/S is founded in 2017 to work with the Danish legalization program for medical cannabis to give better quality of life for patients. The company import’s and sell finished products for the Danish market via distributors. STENOCARE has approvals from the Danish Medicine Agency to supply pharmacies and hospitals with medical cannabis oil products. The company will build a production facility to cultivate and manufacture their own finished medical cannabis products for patients in Denmark and Europe, and thereby command the entire value chain and secure supply capacity. STENOCARE has a strategic partner, CannTrust Inc, that is providing their technology and knowhow for production of medical cannabis.

Subscribe

Documents & Links